# Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

> **NCT03694249** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Malignant Solid Tumor

## Interventions

- **DRUG:** Ifetroban Sodium
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03694249
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-12
- **Primary completion:** 2025-04
- **Final completion:** 2026-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694249, "Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03694249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*